Catherinn BV (Cancer Therapeutics and Innovation) is a virtual research and development company devoted to the improvement of diagnostic and treatment options for Small Cell Lung Cancer (SCLC) patients. Catherinn was started by a group of highly motivated experts and entrepreneurs in the life science and vaccine industry. Important work on SCLC diagnostics and therapy was carried out and patented by the group of prof. Frans Ramaekers, department of molecular cell biology of the Maastricht University Medical Center. In 2014, the patent was acquired by Catherinn BV. We are committed to improving the lives of SCLC cancer patients, both by prevention through early screening and by cure through immunotherapy.
Company Details
- Employees
- 3
- Address
- Rotterdam, Nl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://catherinn.com/
- Keywords
- Novo Nordisk.
- HQ
- Rotterdam
Catherinn Bv Questions
Catherinn Bv's website is https://catherinn.com/
Catherinn Bv's LinkedIn profile is https://nl.linkedin.com/company/catherinn-bv
Catherinn Bv has
3 employees.
View email and phone details for 3
employees at Catherinn Bv.
Catherinn Bv's industry is
Biotechnology Research
Catherinn Bv's top competitors are
Csl,
Genlumina,
Maptimmune,
Nextgen Immuno Therapeutics,
Cast H2020,
Nanoprecision Therapeutics,
Life Science And Process Systems Engineering Lab,
Novo Nordisk,
Hôtel-Dieu De France,
Iprotics.
Catherinn Bv's categories are Biotechnology Research
